Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.

Cancer - 15 Oct 2024

Gener-Ricos Georgina, Bataller Alex, Rodriguez-Sevilla Juan Jose, Chien Kelly S, Quesada Andres E, Almanza-Huante Emmanuel, Hammond Danielle, Sasaki Koji, DiNardo Courtney, Kadia Tapan, Daver Naval, Borthakur Gautam, Issa Ghayas C, Short Nicholas J, Kanagal-Shamanna Rashmi, Kantarjian Hagop M, Garcia-Manero Guillermo, Montalban-Bravo Guillermo

Abstract excerpt

INTRODUCTION: NPM1-mutated (NPM1mut) myeloid neoplasms (MNs) with <20% bone marrow (BM) blasts (NPM1mut MNs<20) are uncommon, and their classification remains inconsistent. METHODS: The clinicopathologic features of 54 patients with NPM1mut MNs <20 were evaluated and compared with wild-type NPM1 MNs <20 and NPM1mut MNs≥20, respectively. RESULTS: NPM1mut MNs had similar features regardless of blast percentage,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Myeloproliferative Disorders

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Prognosis

Share to Young Adult

Source

Identifiers

PMID: 38896064
DOI: 10.1002/cncr.35433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.PMID 38896064Read ↗

NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?Semantic proximity Read ↗

NPM1-mutated myeloid neoplasm with low percentage of blasts.Semantic proximity Read ↗

The NPM1 mutant defines AML irrespective of blast countSemantic proximity Read ↗

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.Semantic proximity Read ↗

Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.Semantic proximity Read ↗

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?Semantic proximity Read ↗

The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.Semantic proximity Read ↗

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemiaSemantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.